J. Michael Hamilton

2.1k total citations
38 papers, 1.6k citations indexed

About

J. Michael Hamilton is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Michael Hamilton has authored 38 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 15 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Michael Hamilton's work include Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (11 papers) and Neutropenia and Cancer Infections (7 papers). J. Michael Hamilton is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (11 papers) and Neutropenia and Cancer Infections (7 papers). J. Michael Hamilton collaborates with scholars based in United States. J. Michael Hamilton's co-authors include Jean L. Grem, Susan S. Ellenberg, Jeffrey Schlom, Seth M. Steinberg, Alice P. Chen, Chris H. Takimoto, Frank Grollman, Anne Bastian, Samir N. Khleif and Carmen J. Allegra and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Hepatology.

In The Last Decade

J. Michael Hamilton

37 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Michael Hamilton United States 19 822 697 544 250 124 38 1.6k
H. Kölbl Germany 24 709 0.9× 814 1.2× 267 0.5× 188 0.8× 243 2.0× 124 2.2k
Neal J. Meropol United States 16 1.1k 1.3× 783 1.1× 382 0.7× 393 1.6× 140 1.1× 31 2.0k
Michael L. Meyers United States 19 772 0.9× 823 1.2× 534 1.0× 249 1.0× 65 0.5× 42 1.6k
Min Huang United States 22 735 0.9× 598 0.9× 198 0.4× 422 1.7× 126 1.0× 94 1.8k
Edward F. McClay United States 21 757 0.9× 403 0.6× 359 0.7× 229 0.9× 173 1.4× 57 1.3k
Luis H. Camacho United States 30 1.8k 2.1× 1.1k 1.5× 1.2k 2.3× 256 1.0× 156 1.3× 104 3.1k
W. P. Peters United States 22 1.1k 1.3× 315 0.5× 174 0.3× 254 1.0× 106 0.9× 59 1.9k
Vanessa M. Hubbard-Lucey United States 17 1.4k 1.7× 659 0.9× 910 1.7× 314 1.3× 94 0.8× 23 2.4k
Dagmar Hess Switzerland 20 897 1.1× 880 1.3× 243 0.4× 368 1.5× 74 0.6× 61 1.7k
Teresa M. Petrella Canada 19 2.3k 2.8× 897 1.3× 828 1.5× 350 1.4× 137 1.1× 44 2.8k

Countries citing papers authored by J. Michael Hamilton

Since Specialization
Citations

This map shows the geographic impact of J. Michael Hamilton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Michael Hamilton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Michael Hamilton more than expected).

Fields of papers citing papers by J. Michael Hamilton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Michael Hamilton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Michael Hamilton. The network helps show where J. Michael Hamilton may publish in the future.

Co-authorship network of co-authors of J. Michael Hamilton

This figure shows the co-authorship network connecting the top 25 collaborators of J. Michael Hamilton. A scholar is included among the top collaborators of J. Michael Hamilton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Michael Hamilton. J. Michael Hamilton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Locarnini, Stephen, Bruce D. Given, Thomas Schluep, et al.. (2019). First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA). Hepatology. 70(6). 7 indexed citations
2.
Rahma, Osama E., J. Michael Hamilton, Sarah Bernstein, et al.. (2014). The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. Journal of Translational Medicine. 12(1). 55–55. 59 indexed citations
3.
Hamilton, J. Michael, et al.. (2008). A Phase I Dose‐Ranging Study of the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of AVN944, an IMPDH Inhibitor, in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 49(1). 30–38. 12 indexed citations
4.
Shord, Stacy S., J. Michael Hamilton, & Sandra Cuéllar. (2008). Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia. Journal of Oncology Pharmacy Practice. 14(1). 5–22. 4 indexed citations
5.
Klisovic, Rebecca B., Guido Tricot, Steven Coutré, et al.. (2007). A phase I trial of AVN944 in patients with advanced hematologic malignancies. Journal of Clinical Oncology. 25(18_suppl). 14026–14026. 3 indexed citations
6.
Grem, Jean L., Mary Quinn, Bruce Keith, et al.. (2003). A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin. Cancer Chemotherapy and Pharmacology. 52(6). 487–496. 4 indexed citations
7.
Harold, Nancy, Muhammad Wasif Saif, Barbara Schüler, et al.. (2003). Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cancer Chemotherapy and Pharmacology. 52(1). 79–85. 13 indexed citations
8.
Gulley, James L., Alice P. Chen, William L. Dahut, et al.. (2002). Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer. The Prostate. 53(2). 109–117. 175 indexed citations
9.
10.
Arlen, Philip M., Kwong-Yok Tsang, John L. Marshall, et al.. (2000). The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunology Immunotherapy. 49(10). 517–529. 62 indexed citations
11.
Grem, Jean L., et al.. (1998). The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer.. Oncology Reports. 5(3). 559–67. 16 indexed citations
12.
Takimoto, Chris H., William L. Dahut, Mark T. Marino, et al.. (1997). Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.. Journal of Clinical Oncology. 15(4). 1492–1501. 39 indexed citations
13.
14.
Dahut, William L., Nancy Harold, Chris H. Takimoto, et al.. (1996). Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.. Journal of Clinical Oncology. 14(4). 1236–1244. 61 indexed citations
15.
Politi, Pedro M., William Dahut, Harry Ford, et al.. (1995). Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology. 36(6). 513–523. 37 indexed citations
16.
17.
Hamilton, J. Michael. (1994). Adjuvant therapy for gastrointestinal cancer. Current Opinion in Oncology. 6(4). 435–440. 3 indexed citations
18.
Grem, Jean L., Nanette McAtee, Robert F. Murphy, et al.. (1991). A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.. Journal of Clinical Oncology. 9(10). 1811–1820. 93 indexed citations
19.
Stevenson, H C, et al.. (1991). Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer.. Journal of Clinical Oncology. 9(11). 2052–2066. 85 indexed citations
20.
Ellenberg, Susan S. & J. Michael Hamilton. (1989). Surrogate endpoints in clinical trials: Cancer. Statistics in Medicine. 8(4). 405–413. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Kölbl Breakdown of academic impact, for papers by Neal J. Meropol Breakdown of academic impact, for papers by Michael L. Meyers Breakdown of academic impact, for papers by Min Huang Breakdown of academic impact, for papers by Edward F. McClay Breakdown of academic impact, for papers by Luis H. Camacho Breakdown of academic impact, for papers by W. P. Peters Breakdown of academic impact, for papers by Vanessa M. Hubbard-Lucey Breakdown of academic impact, for papers by Dagmar Hess Breakdown of academic impact, for papers by Teresa M. Petrella
Rankless by CCL
2026